Bassel Zorkany-El

Cairo, C, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.

The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.

Journal: Annals of the rheumatic diseases

Published: September 18, 2024

Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.

Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.

Journal: Rheumatology and therapy

Published: July 29, 2024

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.

Journal: Advances in rheumatology (London, England)

Published: January 11, 2024

Treat-to-Target in Axial Spondyloarthritis: Are we there yet?

Treat-to-Target in Axial Spondyloarthritis: Are we there yet?

Journal: Mediterranean journal of rheumatology

Published: July 25, 2021

Axial spondyloarthritis.

Axial spondyloarthritis.

Journal: Annals of the rheumatic diseases

Published: June 28, 2021

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis.

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis.

Journal: Rheumatology (Oxford, England)

Published: April 21, 2021

The ASAS-OMERACT core domain set for axial spondyloarthritis.

The ASAS-OMERACT core domain set for axial spondyloarthritis.

Journal: Seminars in arthritis and rheumatism

Published: April 15, 2021

Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.

Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: May 26, 2018

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages.

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages.

Journal: RMD open

Published: May 24, 2016

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.

Journal: Annals of the rheumatic diseases

Published: July 03, 2015

Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis.

Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis.

Journal: Clinical rheumatology

Published: June 08, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026